FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2768356382> ?p ?o ?g. }

• W2768356382 endingPage "754" @default.
• W2768356382 startingPage "742" @default.
• W2768356382 abstract "Inadequate remyelination is central to degeneration and disability in patients with multiple sclerosis (MS); however, all currently approved therapies for MS are primarily immunomodulatory. Here, Martin Stangel and colleagues review our current knowledge of remyelination in MS, discuss results from clinical trials of remyelination-enhancing therapies, and evaluate the opportunities for future regenerative treatments. Remyelination in the CNS is the natural process of damage repair in demyelinating diseases such as multiple sclerosis (MS). However, remyelination becomes inadequate in many people with MS, which results in axonal degeneration and clinical disability. Enhancement of remyelination is a logical therapeutic goal; nevertheless, all currently licensed therapies for MS are immunomodulatory and do not support remyelination directly. Several molecular pathways have been identified as potential therapeutic targets to induce remyelination, and some of these have now been assessed in proof-of-concept clinical trials. However, trial design faces several obstacles: optimal clinical or paraclinical outcome measures to assess remyelination remain ill-defined, and identification of the ideal timing of therapy is also a crucial issue. In addition, realistic expectations are needed concerning the probable benefits of such therapies. Nevertheless, approaches that enhance remyelination are likely to be protective for axons and so could prevent long-term neurodegeneration. Future MS treatment paradigms, therefore, are likely to comprise a combinatorial approach that involves both immunomodulatory and regenerative treatments." @default.
• W2768356382 created "2017-12-04" @default.
• W2768356382 creator A5014510701 @default.
• W2768356382 creator A5048801608 @default.
• W2768356382 creator A5070529061 @default.
• W2768356382 creator A5080712147 @default.
• W2768356382 date "2017-11-17" @default.
• W2768356382 modified "2023-10-18" @default.
• W2768356382 title "Achievements and obstacles of remyelinating therapies in multiple sclerosis" @default.
• W2768356382 cites W1002209064 @default.
• W2768356382 cites W1446040360 @default.
• W2768356382 cites W1485262693 @default.
• W2768356382 cites W1509726604 @default.
• W2768356382 cites W1593681077 @default.
• W2768356382 cites W1603992028 @default.
• W2768356382 cites W1696190749 @default.
• W2768356382 cites W1816022152 @default.
• W2768356382 cites W1828576284 @default.
• W2768356382 cites W1834417670 @default.
• W2768356382 cites W1866034006 @default.
• W2768356382 cites W1901712533 @default.
• W2768356382 cites W1916428876 @default.
• W2768356382 cites W1964416005 @default.
• W2768356382 cites W1964544761 @default.
• W2768356382 cites W1971006243 @default.
• W2768356382 cites W1974656309 @default.
• W2768356382 cites W1975719696 @default.
• W2768356382 cites W1976704496 @default.
• W2768356382 cites W1977213877 @default.
• W2768356382 cites W1982881050 @default.
• W2768356382 cites W1983267695 @default.
• W2768356382 cites W1983378056 @default.
• W2768356382 cites W1985183520 @default.
• W2768356382 cites W1988586000 @default.
• W2768356382 cites W1997970965 @default.
• W2768356382 cites W1998475020 @default.
• W2768356382 cites W1999037903 @default.
• W2768356382 cites W2001188679 @default.
• W2768356382 cites W2001364132 @default.
• W2768356382 cites W2001741486 @default.
• W2768356382 cites W2004006028 @default.
• W2768356382 cites W2005419194 @default.
• W2768356382 cites W2006897862 @default.
• W2768356382 cites W2022146449 @default.
• W2768356382 cites W2023367024 @default.
• W2768356382 cites W2027270401 @default.
• W2768356382 cites W2029817323 @default.
• W2768356382 cites W2029932224 @default.
• W2768356382 cites W2032054191 @default.
• W2768356382 cites W2035098555 @default.
• W2768356382 cites W2035195833 @default.
• W2768356382 cites W2040085463 @default.
• W2768356382 cites W2045850534 @default.
• W2768356382 cites W2048082433 @default.
• W2768356382 cites W2048206988 @default.
• W2768356382 cites W2053166138 @default.
• W2768356382 cites W2053632281 @default.
• W2768356382 cites W2054696265 @default.
• W2768356382 cites W2054710763 @default.
• W2768356382 cites W2055241344 @default.
• W2768356382 cites W2055693317 @default.
• W2768356382 cites W2056677926 @default.
• W2768356382 cites W2058358434 @default.
• W2768356382 cites W2058718560 @default.
• W2768356382 cites W2059528602 @default.
• W2768356382 cites W2060197077 @default.
• W2768356382 cites W2060544102 @default.
• W2768356382 cites W2062326815 @default.
• W2768356382 cites W2067527174 @default.
• W2768356382 cites W2074132398 @default.
• W2768356382 cites W2077702475 @default.
• W2768356382 cites W2078482008 @default.
• W2768356382 cites W2082857050 @default.
• W2768356382 cites W2085879860 @default.
• W2768356382 cites W2089776738 @default.
• W2768356382 cites W2089851064 @default.
• W2768356382 cites W2091353362 @default.
• W2768356382 cites W2094044389 @default.
• W2768356382 cites W2100555346 @default.
• W2768356382 cites W2105209479 @default.
• W2768356382 cites W2105844486 @default.
• W2768356382 cites W2108005154 @default.
• W2768356382 cites W2111256919 @default.
• W2768356382 cites W2111428020 @default.
• W2768356382 cites W2113672425 @default.
• W2768356382 cites W2116653422 @default.
• W2768356382 cites W2117987556 @default.
• W2768356382 cites W2118108707 @default.
• W2768356382 cites W2118746021 @default.
• W2768356382 cites W2125573110 @default.
• W2768356382 cites W2136266325 @default.
• W2768356382 cites W2140916089 @default.
• W2768356382 cites W2141030054 @default.
• W2768356382 cites W2141426770 @default.
• W2768356382 cites W2143742274 @default.
• W2768356382 cites W2143862196 @default.
• W2768356382 cites W2145016172 @default.
• W2768356382 cites W2147062889 @default.

• next